# Ritalin LA ### (methylphenidate hydrochloride extended-release, bimodal beads) **[Ritalin LA](https://wiki.joshnp.com/books/drug-library/page/ritalin-la)** (methylphenidate hydrochloride extended-release, bimodal beads); CII
[**Full Prescribing Information**](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=effd952d-ac94-47bb-b107-589a4934dcca&type=display)[**DailyMed Drug Information**](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=effd952d-ac94-47bb-b107-589a4934dcca)
--- ### **Summary** Ritalin LA is a bead-filled methylphenidate capsule carrying half its dose as immediate-release beads and half as enteric-coated delayed-release beads, reproducing a twice-daily Ritalin regimen in one morning capsule. Its approval is narrower than any other long-acting methylphenidate here: ADHD in children 6 to 12 years only. The capsule can be opened onto applesauce, so it suits a child who cannot swallow. Schedule II; brand and generic. --- ### **Forms & Strengths** - Extended-release capsules (bimodal beads, may be opened onto applesauce): 10 mg, 20 mg, 30 mg, 40 mg, 60 mg --- ### **Dosing** - **Age:** 6 to 12 y/o only; no adolescent and no adult indication - **Onset:** ~ 1 hour - **Duration:** about 8 hours - **Release Profile:** 50% IR / 50% DR via bimodal beads - **Initial Dose:** - New to methylphenidate: 20 mg once daily in the morning; 10 mg where a lower start is appropriate - From Ritalin twice daily, per dose: 5 mg to 10 mg; 10 mg to 20 mg; 15 mg to 30 mg; 20 mg to 40 mg; 30 mg to 60 mg once daily - **Titration:** 10 mg every 7 days - **Max Dose:** 60 mg/day - **Considerations:** Switching from any methylphenidate other than Ritalin means titrating from the start, not converting milligram-for-milligram. Capsules may be opened onto cool applesauce. --- ### **Pharmacology** - **Mechanism:** Blocks presynaptic dopamine and norepinephrine reuptake at DAT and NET; does not meaningfully promote catecholamine release at therapeutic doses - **Delivery / Release:** 50% IR / 50% DR via bimodal beads. Enteric-coated beads release past gastric pH, giving two peaks about 4 hours apart with less fluctuation than two separate tablets. - **Metabolism:** De-esterified to ritalinic acid, inactive. Not a CYP substrate. Half-life 2.5 h in children, 3.5 h in adults. No accumulation once daily. - **Class Positioning:** Two discrete peaks, not an ascending ramp, and a shallower dip than two separate [Ritalin](https://wiki.joshnp.com/link/29) tablets. Against [Metadate CD](https://wiki.joshnp.com/link/24) the split is 50/50 not 30/70; against [Concerta](https://wiki.joshnp.com/link/11) it can be sprinkled but stops at 12. - **Cardiac electrophysiology:** no QT study on this product; the dexmethylphenidate study cited found mean QTcF under 5 ms. --- ### **Indications** - **ADHD** (ICD-10: F90.0, F90.1, F90.2, F90.8, F90.9): patients 6 to 12 y/o --- ### **Off-Label Uses** - **ADHD in adolescents 13 to 17 and in adults** (ICD-10: F90.x): the commonest off-label use; no adolescent efficacy data. Insufficient for this product. (AHRQ 2024) - **ADHD in children 4 to 5 years old** (ICD-10: F90.x): behavioral parent training first line; if medication is needed use IR methylphenidate. Expert consensus. (AAP 2019) - **Narcolepsy** (ICD-10: G47.419): IR methylphenidate carries this indication, Ritalin LA does not. Insufficient. - **Where the evidence does not support use:** treatment-resistant depression, binge eating disorder, cancer-related and chronic fatigue. Adult literature only; insufficient in children. (AHRQ 2024) - **Cognitive enhancement in a youth without ADHD:** not an indication and not supported. --- ### **Contraindications & Warnings** - **Boxed Warning:** Abuse, misuse and addiction, with overdose and death. Assess abuse risk before prescribing and reassess throughout treatment. - **Contraindicated:** - Hypersensitivity to methylphenidate or any component - MAOI use, current or within 14 days: hypertensive crisis - **Use with caution:** - Structural cardiac abnormality, cardiomyopathy, arrhythmia or coronary disease: avoid - Pre-existing hypertension: monitor blood pressure and pulse - Psychotic or bipolar disorder: exacerbation and treatment-emergent mania - Significant hyperopia or angle-closure risk: refer to ophthalmology - Personal or family history of tics or Tourette's syndrome - Substance use disorder in patient or household; beads can be crushed, so this is not abuse-deterrent - **Screen before starting:** - Cardiac history and exam including family sudden death; the label requires no routine ECG - Tics, and risk factors for a manic episode - Abuse and diversion risk in patient and household - Baseline height, weight, blood pressure and heart rate - Age against the 6 to 12 indication; near 13, pick an agent labeled for adolescents --- ### **Drug Interactions** - **MAOIs** (phenelzine, tranylcypromine, selegiline, linezolid, methylene blue): hypertensive crisis. Contraindicated within 14 days. - **Antihypertensives:** effectiveness reduced. Increase BP monitoring and adjust the antihypertensive. - **Halogenated anesthetics** (sevoflurane, isoflurane, desflurane): intraoperative BP and HR surge. Hold on the day of surgery. - **Risperidone:** EPS may increase when either dose changes in either direction. Monitor across any titration; a common pairing in ADHD with aggression. - **Serotonergic agents** (SSRIs, SNRIs, TCAs, triptans, tramadol): serotonin syndrome in postmarketing reports only, not in the interaction table. Counsel on symptoms. --- ### **Administration** - Once daily in the morning; no food timing needed, and no dose dumping. - Swallow whole, or open onto a spoonful of applesauce that is cool, never warm; heat damages the coating on the delayed beads. - Swallow the applesauce mixture at once and entirely, without chewing; never prepare it in advance. - Do not crush, chew or divide the beads; chewing converts the whole dose to immediate release. - Switching from any methylphenidate other than Ritalin: titrate from the beginning, never milligram-for-milligram. - Missed dose: skip it; a late dose puts the delayed bead peak in the evening. - Store locked; an openable bead capsule is straightforward to misuse. --- ### **Side Effects** - **Common:** headache, insomnia, upper abdominal pain, decreased appetite, anorexia. No pediatric percentages published. - **Serious:** - Sudden death with structural cardiac disease: avoid the drug in that population - New psychosis or mania, including with no psychiatric history: consider discontinuing - Priapism, sometimes surgical, typically after a dose increase and also during drug holidays - Peripheral vasculopathy and Raynaud's with digital ulceration: assess digits each visit - Long-term growth suppression; the whole indicated population is prepubertal - Acute angle closure glaucoma; new or worsening tics and Tourette's - Postmarketing: convulsions, choreoathetoid dyskinesia, cerebral vasculitis and hemorrhage, serotonin syndrome --- ### **Monitoring & Labs** - **Growth:** height, weight and BMI at baseline and every 6 months, every visit if losing weight. - **Cardiovascular:** BP and HR at baseline, at every dose change, and at least every 6 months. - **Appetite and sleep:** at every visit and dose change; suppression is heaviest at the morning peak. - **Afternoon coverage:** ask at every visit about the hours after the second peak. Late-afternoon return is expected; change product rather than raise the dose. - **Age against indication:** check at every annual visit. At 13 this becomes off-label with no adolescent efficacy data; plan the switch first. [Concerta](https://wiki.joshnp.com/link/11) is labeled to 65, [Aptensio XR](https://wiki.joshnp.com/link/38) has no upper limit. - **Psychiatric and tics:** screen for psychosis, mania, aggression, depressed mood and tics at baseline and every visit. - **Abuse and diversion:** at every refill, capsule count, ask about sharing and selling, check the PDMP. A capsule made to be opened is not abuse-deterrent. - **Laboratory:** none is required by this label. --- ### **Discontinuation & Taper** - No taper required; the label gives no tapering schedule. - Discontinue if no improvement after appropriate dose adjustment over one month. - Withdrawal after prolonged use: dysphoria, fatigue, vivid dreams, sleep change, increased appetite. - Priapism has occurred during drug holidays and on discontinuation. - Drug holidays are reasonable where growth limits treatment; a capsule cannot be part-dosed. - Switching to another methylphenidate: titrate the new product from its own starting dose. --- ### **Pregnancy & Lactation** - **Pregnancy:** no drug-associated risk of major birth defects or miscarriage identified. Stimulant vasoconstriction may reduce placental perfusion. Background risk 2% to 4% and 15% to 20%. - **Lactation:** infant dose 0.16% to 0.7% of the maternal weight-adjusted dose; undetectable in infant serum in every reported case. Not a reason to stop breastfeeding. (LactMed 2025) - **Lactation, milk supply:** prolactin falls; large doses may interfere before supply is established. Monitor the infant for agitation, insomnia and poor weight gain. (LactMed 2025) - **Exposure Registry:** National Pregnancy Registry for ADHD Medications, 1-866-961-2388, [womensmentalhealth.org/adhd-medications](https://womensmentalhealth.org/adhd-medications/). --- ### **Counseling Points** - **Counsel the family on:** - The applesauce rule: cool never warm, swallowed at once, never chewed, never made up in advance. - The two-peak pattern: a mid-morning lull is not a failed dose. - Coverage reaching early afternoon, not evening; if homework is the problem, this is the wrong product. - Giving breakfast before the capsule; the morning half is what flattens appetite. - Never chewing the beads; chewed beads turn a full-day dose into one immediate-release hit. - The 6 to 12 approval, so the plan will change in adolescence. Say it early, or the switch reads as failure. - Locked storage; a capsule of loose beads is easily emptied. - **Advise them to call for:** - Chest pain, fainting, or a racing heart that does not settle. - New hallucinations or suspicious thinking; eye pain with halos around lights. - Numbness, coldness or colour change in fingers or toes, or a sore that will not heal. - A new or markedly worse tic, including throat clearing and blinking. - A painful erection lasting more than a few hours, including during a planned break. - Any seizure, or a jerking movement the child cannot stop. - Clothes fitting more loosely, or no weight gain across a few months. --- ### **References** 1. DailyMed. Ritalin LA (methylphenidate hydrochloride) extended-release capsules prescribing information. Novartis Pharmaceuticals Corporation. 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=effd952d-ac94-47bb-b107-589a4934dcca 2. FDA. openFDA National Drug Code Directory, generic\_name methylphenidate. 2026. https://api.fda.gov/drug/ndc.json?search=generic\_name:%22methylphenidate%22&limit=1000 3. LactMed. Methylphenidate. Drugs and Lactation Database, NICHD. 2025. https://www.ncbi.nlm.nih.gov/books/NBK501310/ 4. American Academy of Pediatrics. Clinical practice guideline for the diagnosis, evaluation, and treatment of ADHD in children and adolescents. Pediatrics. 2019. https://publications.aap.org/pediatrics/article/144/4/e20192528/81590/ 5. AHRQ. Attention deficit hyperactivity disorder: diagnosis and treatment in children and adolescents. Comparative Effectiveness Review No. 267. 2024. https://www.ncbi.nlm.nih.gov/books/NBK602989/